XNASSHC
Market cap3.79bUSD
Jan 10, Last price
13.11USD
1D
-0.74%
1Q
-11.91%
IPO
-52.09%
Name
Sotera Health Co
Chart & Performance
P/E
72.28
P/S
3.54
EPS
0.18
Div Yield, %
0.00%
Shrs. gr., 5y
2.85%
Rev. gr., 5y
7.06%
Revenues
1.05b
+4.54%
Net income
51m
P
CFO
-148m
L
Earnings
Feb 25, 2025
Profile
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 1,049,288 4.54% | 1,003,687 7.75% | ||||
Cost of revenue | 472,130 | 446,683 | ||||
Unusual Expense (Income) | ||||||
NOPBT | 577,158 | 557,004 | ||||
NOPBT Margin | 55.00% | 55.50% | ||||
Operating Taxes | 54,651 | (9,541) | ||||
Tax Rate | 9.47% | |||||
NOPAT | 522,507 | 566,545 | ||||
Net income | 51,376 -122.00% | (233,570) -299.83% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (4,089) | (393) | ||||
BB yield | 0.09% | 0.02% | ||||
| Debt | ||||||
Debt current | 34,207 | 206,395 | ||||
Long-term debt | 2,406,139 | 1,834,923 | ||||
Deferred revenue | 18,762 | 18,902 | ||||
Other long-term liabilities | 65,262 | 141,859 | ||||
Net debt | 2,129,157 | 1,610,260 | ||||
| Cash flow | ||||||
Cash from operating activities | (147,732) | 277,961 | ||||
CAPEX | (214,975) | (182,378) | ||||
Cash from investing activities | (214,906) | (181,896) | ||||
Cash from financing activities | 265,959 | 197,761 | ||||
FCF | 289,271 | 544,605 | ||||
| Balance | ||||||
Cash | 301,654 | 396,294 | ||||
Long term investments | 9,535 | 34,764 | ||||
Excess cash | 258,725 | 380,874 | ||||
Stockholders' equity | (744,262) | (809,609) | ||||
Invested Capital | 3,613,781 | 3,265,684 | ||||
ROIC | 15.19% | 17.95% | ||||
ROCE | 19.67% | 22.07% | ||||
| EV | ||||||
Common stock shares outstanding | 283,222 | 280,096 | ||||
Price | 16.85 102.28% | 8.33 -64.63% | ||||
Market cap | 4,772,291 104.54% | 2,333,200 -64.54% | ||||
EV | 6,901,448 | 3,943,460 | ||||
EBITDA | 737,496 | 702,558 | ||||
EV/EBITDA | 9.36 | 5.61 | ||||
Interest | 142,878 | 80,144 | ||||
Interest/NOPBT | 24.76% | 14.39% | ||||